Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
暂无分享,去创建一个
Geoffrey R. Oxnard | Ross A. Soo | Matthew Meyerson | Kota Ishioka | Megan Hanna | M. Meyerson | M. Hanna | L. Sequist | M. Arcila | Gregory Riely | S. Kobayashi | M. Eck | D. Costa | J. Chaft | C. Yun | R. Soo | David W. Cohen | G. Oxnard | T. Morán | Maria E. Arcila | Gregory J. Riely | Lecia V. Sequist | Teresa Moran | C. Lathan | Hiroyuki Yasuda | Eunyoung Park | Cai-Hong Yun | Natasha J. Sng | Antonio R. Lucena-Araujo | Wee-Lee Yeo | Mark S. Huberman | Sohei Nakayama | Norihiro Yamaguchi | Christopher S. Lathan | Jamie E. Chaft | Michael J. Eck | Susumu S. Kobayashi | Daniel B. Costa | A. Lucena-Araújo | E. Park | M. Huberman | W. Yeo | Natasha J. L. Sng | H. Yasuda | N. Yamaguchi | Sohei Nakayama | Kota Ishioka | Eunyoung Park
[1] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[2] G. Murshudov,et al. Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.
[3] R J Read,et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.
[4] E K Rowinsky,et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] A. Harris,et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[7] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[8] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[9] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[10] A. W. Schüttelkopf,et al. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.
[11] M. Meyerson,et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. , 2005, Cancer research.
[12] S. Toyooka,et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] M. Ostland,et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Minna,et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.
[15] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[16] W. Pao,et al. Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.
[17] H. Varmus,et al. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. , 2006, Genes & development.
[18] P. Jänne,et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. , 2006, Cancer cell.
[19] Stuart Thomson,et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. , 2006, Cancer research.
[20] John Kuriyan,et al. An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.
[21] D. Haber,et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Derek Y. Chiang,et al. Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.
[23] Y. Yatabe,et al. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer , 2007, Cancer science.
[24] D. Tenen,et al. BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations , 2007, PLoS medicine.
[25] M. Meyerson,et al. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272 , 2007, Oncogene.
[26] A. Strasser,et al. Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 Mimetics , 2007, PLoS medicine.
[27] H. Sasaki,et al. EGFR exon 20 insertion mutation in Japanese lung cancer. , 2007, Lung cancer.
[28] Matthew Meyerson,et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. , 2007, Cancer cell.
[29] D. Tenen,et al. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. , 2007, Lung cancer.
[30] D. Haber,et al. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. , 2007, Cancer research.
[31] S. Gabriel,et al. High-throughput oncogene mutation profiling in human cancer , 2007, Nature Genetics.
[32] W. Pao,et al. Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas , 2007, PLoS medicine.
[33] M. Meyerson,et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. , 2007, Cancer research.
[34] Daniel A. Haber,et al. Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.
[35] A. Letai,et al. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. , 2007, Cancer research.
[36] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[37] Alona Muzikansky,et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] P. Jänne,et al. Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib , 2008, Clinical Cancer Research.
[39] M. Meyerson,et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models , 2008, Oncogene.
[40] Yih-Leong Chang,et al. Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response , 2008, Clinical Cancer Research.
[41] Issa J Dahabreh,et al. Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung Cancer: An Analytical Database , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[42] M. Meyerson,et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.
[43] S. Kobayashi,et al. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. , 2009, Clinical lung cancer.
[44] John R. Engen,et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.
[45] Issa J. Dahabreh,et al. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC , 2009, Nature Reviews Clinical Oncology.
[46] John Kuriyan,et al. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3 , 2009, Proceedings of the National Academy of Sciences.
[47] Mariano Provencio,et al. Screening for epidermal growth factor receptor mutations in lung cancer. , 2009, The New England journal of medicine.
[48] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[49] A. Gemma,et al. F1000 highlights , 2010 .
[50] M. Eck,et al. Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. , 2010, Biochimica et biophysica acta.
[51] William Pao,et al. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer , 2010, Nature Reviews Cancer.
[52] Susan Quinn,et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] Y. Yatabe,et al. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer , 2010, The FEBS journal.
[54] M. Kris,et al. Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[55] R. Plummer,et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] Young Lim Choi,et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. , 2010, The New England journal of medicine.
[57] Lin Huan,et al. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer , 2010 .
[58] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[59] M. Ladanyi,et al. EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma , 2011, Clinical Cancer Research.
[60] Jun Ma,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.
[61] J. Shih,et al. Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer , 2011, Clinical Cancer Research.
[62] G. Giaccone,et al. Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry , 2011, Oncogene.
[63] L. Sequist,et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] L. Tanoue. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR , 2011 .
[65] S. Kobayashi,et al. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. , 2012, The Lancet. Oncology.
[66] Juswinder Singh,et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. , 2013, Cancer discovery.
[67] J. Settleman,et al. Noncovalent wild-type-sparing inhibitors of EGFR T790M. , 2013, Cancer discovery.
[68] M. Meyerson,et al. Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. , 2013, Cancer research.
[69] A. Jemal,et al. Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.
[70] Marc Ladanyi,et al. EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics , 2013, Molecular Cancer Therapeutics.
[71] William Pao,et al. DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A Catalog of Clinically Relevant Cancer Mutations to Enable Genome-Directed Anticancer Therapy , 2013, Clinical Cancer Research.
[72] Suzanne E Dahlberg,et al. Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[73] Jerrold R. Griggs,et al. The partition method for poset-free families , 2013, J. Comb. Optim..
[74] Chun-Ming Tsai,et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] M. Meyerson,et al. Structural, biochemical, and clinical characterization of Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations in lung cancer (Science Translational Medicine (2014) 6, (225er1)) , 2014 .